WESTON, Mass.-- Biotech drugmaker Biogen Idec Inc. said Thursday its profit grew more than 13 percent in the third quarter, led by sales of the company's multiple sclerosis treatment Avonex. The Massachusetts- based company said revenue from Avonex grew 8 percent to $736.2 million in the period.
Oct 25- Biogen Idec Inc on Thursday reported higher-than-expected third-quarter profit on increased sales of its drugs for multiple sclerosis and cancer, and the U.S. biotechnology company raised its full-year earnings forecast. Biogen posted a net profit of $398 million, or $1.67 per share, compared with a profit of $354 million, or $1.43 per share, a year ago.
Elan Corp. PLC reported a third-quarter loss Wednesday, as heavy charges tied to a business spinoff and the discontinuation of an Alzheimer's drug study weighed on the Irish drugmaker's performance.
NEW YORK-- Shares of Biogen Idec Inc. continued to slump Friday after the company said the Food and Drug Administration has delayed a decision on its multiple sclerosis pill BG-12.
NEW YORK-- Shares of XenoPort Inc. fell Friday after a Piper Jaffray analyst downgraded the stock, saying the company's experimental multiple sclerosis drug is years away from marketing approval or a development partnership.
*UBS cuts Idenix price target to $9 from $10. *UBS raises Celgene price target to $82 from $80. Reuters Station users, click. 1568.
Oct 12- Biogen Idec Inc:. *New data from phase 3 studies provide additional evidence supporting. treatment effect for oral bg-12 in multiple sclerosis.
European regulators have rejected Celgene’s request for an expanded approval of its multiple myeloma drug Revlimid to treat newly diagnosed patients, a stunning setback that slams the brakes on the company's growth.
Whether or not policymakers assist Spain’s struggling economy will make a big difference on how stocks perform next week.
The "Mad Money" host shares his earnings expectations for Biogen Idec, Cummins, Emerson Electric and Chesapeake Energy.
Here’s what “Mad Money” host Jim Cramer expects of select earnings in the days to come.
Since the S&P 500 touched a multi-year high on April 2, the index is down about 3.8 percent. Should investors use the selloff as a buying opportunity?
The Spectrum Pharmaceuticals growth party is over.
Take a look at some of Wednesday’s morning movers:
Technology stocks have been gaining momentum in 2012, up eight of the last nine weeks. However, over the last 12 months, consumer discretionary and health care companies have really powered the rally.
Could there be a correlation between leap years and market performance?
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Although selecting the best of breed in the dog show may be a mysterious science to some, picking outliers in the stock market is vastly more straightforward.
Cramer thinks big pharma stocks could soon pop, so here's his preferred plays.
Find out why he’s bullish on this biotech name.